用于套细胞淋巴瘤的布雷西尤单抗自体白细胞介素-2治疗嵌合抗原受体T细胞（CAR-T）疗法后发生的治疗相关急性髓系白血病
Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma.
作者信息
Volery François, Banz Yara, Heini Alexander, Kronig Marie-Noelle, Siegrist Daniel, Daskalakis Michael, Bacher Ulrike, Pabst Thomas
机构信息
Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
出版信息
Case Rep Oncol. 2024 Sep 26;17(1):1087-1093. doi: 10.1159/000541256. eCollection 2024 Jan-Dec.
INTRODUCTION
The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging.
CASE PRESENTATION
We report the case of a patient developing acute erythroid leukemia with biallelic inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma. The patient presented with a healthy bone marrow prior to lymphoma treatments.
DISCUSSION
Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.
引言
嵌合抗原受体T细胞（CAR-T）疗法用于复发/难治性（r/r）套细胞淋巴瘤的治疗提高了这些患者的生存率。随着该疗法在临床常规治疗中的应用，CAR-T细胞治疗后的长期事件日益显现。
病例报告
我们报告了1例r/r套细胞淋巴瘤患者在接受布雷西尤单抗自体白细胞（brexu-cel）CAR-T治疗26个月后发生双等位基因失活的急性红白血病的病例。该患者在淋巴瘤治疗前骨髓健康。
讨论
CAR-T治疗后继发性恶性肿瘤似乎更为常见。需要更多研究来评估CAR-T细胞疗法的潜在长期毒性，包括继发性髓系恶性肿瘤的发生率。
Zotero 插件